Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,429,589 papers from all fields of science
Search
Sign In
Create Free Account
PPP2R1A gene
Known as:
PR65A
, PPP2R1A
, protein phosphatase 2A, regulatory subunit A, alpha isoform
Expand
This gene plays a role in the regulation of cell growth and division.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
12 relations
Apoptosis
Cell Proliferation Regulatory Process
Chromosome Segregation
DNA Replication
Expand
Narrower (1)
PPP2R1A wt Allele
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Identification of key genes and transcription factors in aging mesenchymal stem cells by DNA microarray data.
Yang’ou Wu
,
Jing Yang
,
Zexin Ai
,
Miao Yu
,
Jia Li
,
Shengjiao Li
Gene
2019
Corpus ID: 58562607
2019
2019
Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
K. Haines
,
Gloria S. Huang
Cancer Research
2019
Corpus ID: 201020112
Critically important to reducing uterine cancer mortality is the development of more effective therapy for aggressive endometrial…
Expand
Review
2019
Review
2019
Das un- und dedifferenzierte Endometriumkarzinom
A. Höhn
,
C. Brambs
,
S. Opitz
,
R. Erber
,
A. Hartmann
,
L. Horn
Der Pathologe
2019
Corpus ID: 204962418
Das undifferenzierte Endometriumkarzinom (ECX) stellt eine epitheliale Neoplasie des Endometriums ohne eindeutige weitere…
Expand
2018
2018
PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma
K. Akaike
,
Y. Suehara
,
+14 authors
Tsuyoshi Saito
OncoTarget
2018
Corpus ID: 44140707
To better characterize the oncogenic role of the PAX3-FOXO1 fusion protein in the acquisition of aggressive behavior in ARMS, we…
Expand
2017
2017
A Selected Immunohistochemical Panel Aids in Differential Diagnosis and Prognostic Stratification of Subtypes of High-grade Endometrial Carcinoma: A Clinicopathologic and Immunohistochemical Study at…
O. Taşkın
,
S. Onder
,
+4 authors
E. Yavuz
Applied immunohistochemistry & molecular…
2017
Corpus ID: 40799379
This study aimed to investigate whether a selected immunohistochemical panel (estrogen receptor, p53, ARID1A, PPP2R1A, HNF-1&bgr…
Expand
2015
2015
Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis
Dawn R. Christianson
,
A. Dobroff
,
+16 authors
R. Pasqualini
Proceedings of the National Academy of Sciences…
2015
Corpus ID: 8813301
Significance Formation of metastasis is the most deadly step in melanoma progression and primarily occurs through the lymphatic…
Expand
2013
2013
Functional Genetic Polymorphisms in PP2A Subunit Genes Confer Increased Risks of Lung Cancer in Southern and Eastern Chinese
Rongrong Yang
,
Lei Yang
,
+7 authors
Jiachun Lu
PLoS ONE
2013
Corpus ID: 6304893
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and functions as a tumor suppressor that…
Expand
Review
2012
Review
2012
430 Analysis of 2,700 Cancer Exomes to Identify Novel Cancer Drivers and Therapeutic Opportunities
S. Tomlins
,
P. Wyngaard
,
+4 authors
D. Rhodes
2012
Corpus ID: 72793089
2011
2011
Identification and functional analyses of polymorphism haplotypes of protein phosphatase 2A-Aα gene promoter.
Yu-Chun Lin
,
Hui-Feng Chen
,
+8 authors
Zhong-Ning Lin
Mutation research
2011
Corpus ID: 27551873
2011
2011
Protein array screening reveals IgA autoantigenicity patterns predicting anti-TNFα therapy response in rheumatoid arthritis patients
Z. Konthur
,
Katja Köpke
,
Annette Poch-Hasnek
,
H. Lehrach
,
G. Burmester
,
K. Skriner
2011
Corpus ID: 71364614
Background One third of rheumatoid arthritis (RA) patients treated with biologicals targeting tumour necrosis factor α (TNFα) are…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE